Table 1. Baseline demographic and clinicopathologic characteristics in the three subgroups.
| Characteristic | EGFR mu (%) | ALK re (%) | EGFR/ALK (+) (%) | Total (%) | P |
|---|---|---|---|---|---|
| Gender | 0.206 | ||||
| Male | 33(39.3%) | 13(56.5%) | 3(27.3%) | 49(41.5%) | |
| Female | 51(60.7%) | 10(43.5%) | 8(72.7%) | 69(58.5%) | |
| Age (median) | 63(38-85) | 48(26-75) | 59(40-71) | 60.5(26-85) | <0.001* |
| WHO PS | 0.061 | ||||
| 0-1 | 81(96.4%) | 19(82.6%) | 10(90.9%) | 110(93.2%) | |
| 2-3 | 3(3.6%) | 4(17.4%) | 1(9.1%) | 8(6.8%) | |
| Smoking history | 0.377 | ||||
| Non smoker | 69(82.1%) | 20(87.0%) | 11(100.0%) | 100(84.7%) | |
| Heavy smoker | 15(17.9%) | 3(13.0%) | 0(0.0%) | 18(15.3%) | |
| Histology | 1.000 | ||||
| AC | 82(97.6%) | 23(100%) | 11(100.0%) | 116(98.3%) | |
| SCC | 2(2.4%) | 0(0.0%) | 0(0.0%) | 2(1.7%) | |
| Clinical stage | 0.343 | ||||
| III | 2(2.4%) | 0(0.0%) | 1(9.1%) | 3(2.5%) | |
| IV | 82(97.6%) | 23(100.0%) | 10(90.9%) | 115(97.5%) | |
| Total | 84(71.2%) | 23(19.5%) | 11(9.3%) | 118(100.0%) |
Aberrations: mu, mutation; re, rearrangement; WHO PS, World Health Organization performance status; SCC, squamous cell carcinoma; AC, adenocarcinoma. EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; A heavy smoker was defined as a patient who had smoked >100 cigarettes in his or her lifetime or that had stopped smoking less than 15 years and had a total of ≥10 pack-year of smoking.
*
The age in three groups was analyzed with the use of Wilcoxon test